Evidence map›Paper›PMID 36578553›Full record

ArticleFrontiers in pharmacology2022

Cerebrospinal fluid concentrations of fluoroquinolones and carbapenems in tuberculosis meningitis.

Nicole F Maranchick, Mohammad H Alshaer, Alison G C Smith, Teona Avaliani, Mariam Gujabidze, Tinatin Bakuradze, Shorena Sabanadze, Zaza Avaliani, Maia Kipiani, Charles A Peloquin and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Contezolid in tuberculous meningitis: comparable efficacy and favorable safety.Frontiers in cellular and infection microbiology · 2026
    Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Pharmacology of emerging drugs for the treatment of multi-drug resistant tuberculosis.Journal of clinical tuberculosis and other mycobacterial diseases · 2024
    Review
  10. Observational
  11. Role of therapeutic drug monitoring in the treatment of multi-drug resistant tuberculosis.Journal of clinical tuberculosis and other mycobacterial diseases · 2024
    Article
  12. ISCCM Position Statement on the Approach to and Management of Critically Ill Patients with Tuberculosis.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2024
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Standards for clinical trials for treating TB.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2023
    Article
  18. Review
  19. First Case of Meningoencephalitis and Bacteraemia withEuropean journal of case reports in internal medicine · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Nicole F MaranchickInfectious Disease Pharmacokinetics Lab, Emerging Pathogens Institute, University of Florida, Gainesville, FL, United States.
Mohammad H AlshaerInfectious Disease Pharmacokinetics Lab, Emerging Pathogens Institute, University of Florida, Gainesville, FL, United States.
Alison G C SmithDepartment of Medicine, Division of Internal Medicine, Duke University, Durham, NC, United States.
Teona AvalianiNational Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia.
Mariam GujabidzeNational Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia.
Tinatin BakuradzeNational Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia.
Shorena SabanadzeNational Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia.
Zaza AvalianiNational Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia.
Maia KipianiNational Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia.
Charles A PeloquinInfectious Disease Pharmacokinetics Lab, Emerging Pathogens Institute, University of Florida, Gainesville, FL, United States.
Russell R KempkerDepartment of Medicine, Division of Infectious Diseases, Emory University, Atlanta, GA, United States.
National Center for Tuberculosis and Lung Disease · GEUniversity of Florida · USDuke University · USEmory University · US

Funding

Emory/Georgia TB Research Advancement Center (TRAC)P30AI168386 · NIAID · EMORY UNIVERSITY · PI Neel Rajnikant Gandhi · 2022 to 2026
$5.8M
Emory-Georgia TB Research Training ProgramD43TW007124 · FIC · EMORY UNIVERSITY · PI HENRY M BLUMBERG, Nestani Tukvadze · 2004 to 2026
$4.6M
FIC NIH HHS D43 TW007124NIAID NIH HHS P30 AI168386
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

antitubercular agentscarbapenemscerebrospinal fluidfluoroquinolonespharmacokineticstuberculosis meningitis

Identifiers

PMID36578553
PMCPMC9791083
OpenAlexW4312123574

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.